Danielle J. Brown
April 15, 2026
Excerpt:
“Health care advocates on Wednesday hailed recent steps to limit how much state health plans will pay for a popular Type 2 diabetes drug, a move that could save state and local governments an estimated $320,000 a year.
That’s a drop in the bucket compared to the recently approved state budget of $70.8 billion, but it’s the first step toward millions in potential savings as the Prescription Drug Affordability Board takes up more high-cost drugs to negotiate lower costs in the future, advocates say.”
“It is a tremendous step forward,” said Vincent DeMarco, president of Maryland Health Care for All, after an event celebrating the board’s recent decision to set an “upper payment limit” on a high-cost drug – a goal it’s been working toward for about seven years.
“Basically, we’re thrilled,” DeMarco said. “We wish it had been sooner”
Read the full article on Maryland Matters
Last modified: April 30, 2026
